Sound Waves Treat Prostate Cancer With Fewer Side Effects

Main Category: Prostate / Prostate Cancer
Also Included In: Cancer / Oncology
Article Date: 05 Jul 2009 - 1:00 PST

email to a friend   printer friendly   opinions  

An Experimental cancer therapy for prostate cancer may be able to treat men without surgery and offer fewer side effects according to the results of a UK study published in the British Journal of Cancer* today (Wednesday).

A group of 172 men with prostate cancer that had not spread were treated under general anaesthetic with High-Intensity-Focused Ultrasound (HIFU) - which uses sound waves to kill cancer cells. The trial took place at two centres - University College Hospital in London and the privately owned Princess Grace Hospital, also in London.

The men taking part in the trial were discharged on average five hours after receiving the HIFU treatment. Typically men with prostate cancer are treated with either surgery or radiotherapy. Surgery usually requires a two to three day inpatient stay and radiotherapy requires daily treatment as an outpatient for up to one month.

Of the initial group, 159 men were followed up a year later and 92 per cent did not have any recurrence of prostate cancer. Although this was not a comparative study, it would be expected that traditional treatments for early prostate cancer of surgery or radiotherapy would show a similar percentage of men showing no recurrence of their prostate cancer one year on.

Less than one percent - one man of the 159 followed up - had incontinence. And 30-40 per cent had impotence. None had any bowel problems.

One year following the traditional treatments of surgery and radiotherapy it would be expected that 5-20 per cent of patients would have incontinence and half have impotence. Radiotherapy can also cause side-effects such as diarrhoea, pain and bleeding in 5-20 per cent of people treated.

Dr Hashim Ahmed from UCL's division of surgical and interventional science, who ran the trial, said: "This study suggests it's possible that HIFU may one day play a role in treating men with early prostate cancer with fewer side effects. But we don't yet know for sure if HIFU is more effective than traditional treatments so it will be important to carry out further studies involving a larger number of patients followed over a longer period of time to truly compare the long term effectiveness of this treatment."

High-Intensity-Focused-Ultrasound or HIFU uses high frequency sound waves to heat up small accurately-targeted amounts of tissue to a temperature of 80-90-C. It can be used to treat the whole prostate, as in this study, or just the cancer areas.

Professor Peter Johnson, chief clinician at Cancer Research UK, said: "This technique needs careful evaluation to make sure that it can produce the same results as the proven treatments for early prostate cancer. If the treatment can be shown to have less side effects then that will be excellent news, but more research is needed to show this. Cancer Research UK is funding a trial to look at this question and we hope that further studies can be carried out to compare HIFU to standard treatments".

Notes

Ahmed et al. High-Intensity-Focused Ultrasound in the treatment of primary prostate cancer: the first UK series. 1 July, 2009. British Journal of Cancer.

The senior investigator for this trial was Dr Mark Emberton, clinical director for cancer services at University College London Hospitals NHS Foundation Trust (UCLH).

To search for UK cancer trials visit Cancer Research UK's clinical trials database on our patient information website CancerHelp UK (http://www.cancerhelp.org.uk) or call Cancer Research UK's specialist information nurses on freephone 0808 800 4040. Lines are open from 9am to 5pm, Monday to Friday.

About HIFU

HIFU doesn't pass through either solid bone or air so it can not treat every type of cancer. It has been tested on prostate cancer, kidney cancer, primary and secondary liver cancer, pancreatic cancer and bladder cancer. NICE guidelines in 2008 state that HIFU is only available through clinical trials, or provided the treatment data is put into a national urology registry.

UKHIFU Ltd is the exclusive UK distributor of the Sonablate ®500 HIFU device which is used at UCLH. The team of technologists at UKHIFU are available to answer technical treatment related questions from doctors, patients and other interested parties on 01761 415570 or info@ukhifu.co.uk, or go to the website for more information http://www.ukhifu.co.uk

About University College London Hospitals NHS Foundation Trust (UCLH)

University College London Hospitals NHS Foundation Trust (UCLH), situated in the West End of London, is one of the largest NHS trusts in the United Kingdom and provides first class acute and specialist services.

The new state-of-the-art University College Hospital which opened in 2005, is the focal point of the trust alongside five cutting-edge specialist hospitals.

The Trust is committed to research and development and forms part of UCL Partners which in March 2009 was officially designated as one of the UK's first academic health science centres by the Department of Health.

Source
University College London

• Additional
• References
• Citations